Table 2.
Summary of patient characteristics
| Model-building data | External validation data | |||
|---|---|---|---|---|
| N | Mean (SD) Median [range] |
N | Mean (SD) Median [range] |
|
| BWT | 1792 | 76.8 (24.2) 74.8 [38.6–195] |
146 | 58.6 (19.0) 57.0 [36.4–95.6] |
| AGE | 1792 | 58.0 (19.5) 59.0 [20.0–88.0] |
146 | 57.2 (15.9) 40.0 [27.0–52.0] |
| BSA | 1675 | 1.87 (12.8) 1.86 [1.33–3.07] |
146 | 1.59 (10.4) 1.58 [1.17–2.14] |
| ALBU | 1059 | 38.5 (13.9) 39.0 [19.0–55.0] |
146 | 40.4 (10.3) 40.0 [27.0–52.0] |
| TPRO | 1055 | 72.3 (8.7) 72.0 [47.0–101] |
146 | 71.4 (7.0) 71.0 [54.0–85.0] |
| BALT | 1074 | 31.5 (122.1) 22.0 [3.00–696] |
146 | 23.0 (66.9) 18.5 [7.0–114] |
| BAST | 1072 | 32.6 (101.6) 23.0 [1.10–516] |
146 | 27.1 (65.7) 21.5 [11.0–158] |
| BALP | 1071 | 161 (90.1) 109 [2.10–1564] |
146 | 289 (49.1) 254 [118–1020] |
| BBIL | 1069 | 7.87 (73.4) 6.50 [2.00–93.0] |
146 | 10.0 (37.9) 10.3 [3.42–25.6] |
| BSCR | 1753 | 78.4 (26.9) 74.0 [26.5–212] |
146 | 56.6 (23.1) 55.7 [33.6–88.4] |
| CRCL | 1753 | 97.3 (37.2) 91.0 [25.4–359] |
146 | 97.5 (28.3) 95.0 [50.6–195] |
| Gender | 1792 | Female: 843 (47 %) Male: 949 (53 %) |
146 | Female: 103 (70.5 %) Male: 43 (29.5 %) |
| Race | 1113 | Caucasian: 929 (51.8 %) Asian: 67 (3.7 %) Black: 49 (2.7 %) Hispanic: 17 (0.9 %) Other: 51 (2.8 %) |
146 | Asian: 146 (100 %) |
| Renal function | 1753 | Normal: 891 (49.7 %) Mild impairment: 666 (37.2 %) Moderate impairment: 196 (10.9 %) |
146 | Normal: 81 (55.5 %) Mild impairment: 58 (39.7 %) Moderate impairment: 7 (4.8 %) |
| Concomitant treatment | 1792 | Single agent: 104 (5.8 %) Chemotherapy: 1586 (88.5 %) Interferon alpha: 102 (5.7 %) |
146 | Single agent: 18 (12.3 %) Chemotherapy: 128 (87.7 %) |
ALBU baseline albumin (g/L), BSA baseline surface area (m2), BWT baseline body weight (kg), N number of patients with available data, SD standard deviation, TPRO baseline total protein (g/L)